In yesterday’s Wall Street session, Elevation Oncology Inc. (NASDAQ:ELEV) shares traded at $0.92, down -20.00% from the previous session.
As of this writing, 4 analysts cover Elevation Oncology Inc. (NASDAQ:ELEV). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $1.00, we find $2.50. Given the previous closing price of $1.15, this indicates a potential upside of 117.39 percent. ELEV stock price is now -5.02% away from the 50-day moving average and -39.89% away from the 200-day moving average. The market capitalization of the company currently stands at $21.34M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $2.50 as their price target over the next twelve months.
With the price target of $12, H.C. Wainwright recently initiated with Buy rating for Elevation Oncology Inc. (NASDAQ: ELEV).
In other news, venBio Global Strategic Fund I, 10% Owner sold 702,737 shares of the company’s stock on May 25. The stock was sold for $2,897,806 at an average price of $4.12. Upon completion of the transaction, the 10% Owner now directly owns 1,905,430 shares in the company, valued at $1.75 million. Insiders disposed of 762,931 shares of company stock worth roughly $0.7 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ELEV stock. A new stake in Elevation Oncology Inc. shares was purchased by ANNANDALE CAPITAL, LLC during the first quarter worth $28,000. In total, there are 35 active investors with 73.00% ownership of the company’s stock.
Tuesday morning saw Elevation Oncology Inc. (NASDAQ: ELEV) opened at $1.0842. During the past 12 months, Elevation Oncology Inc. has had a low of $0.72 and a high of $5.92. As of last week, the company has a debt-to-equity ratio of 0.44, a current ratio of 7.30, and a quick ratio of 7.30. The fifty day moving average price for ELEV is $0.9686 and a two-hundred day moving average price translates $1.5304 for the stock.
The latest earnings results from Elevation Oncology Inc. (NASDAQ: ELEV) was released for Jun, 2022.
Elevation Oncology Inc.(ELEV) Company Profile
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company’s lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
